Table IV.
Correlation of CD44/CD24 status with pathology, androgen receptor and vimentin.
| CD44/CD24 status, n (%) | |||||
|---|---|---|---|---|---|
| Characteristics | CD44−/CD24− | CD44+/CD24− | CD44+/CD24+ | CD44−/CD24+ | P-value |
| Pathology | 0.011 | ||||
| Intraductal carcinoma | 0 (0.0) | 4 (9.1) | 0 (0.0) | 0 (0.0) | |
| Invasive ductal carcinoma | 61 (96.8) | 37 (84.1) | 4 (80.0) | 30 (90.9) | |
| Invasive lobular carcinoma | 2 (3.2) | 1 (2.3) | 1 (20.0) | 0 (0.0) | |
| Other types | 0 (0.0) | 2 (4.5) | 0 (0.0) | 3 (9.1) | |
| Androgen receptor | 0.022 | ||||
| Negative | 59 (93.7) | 33 (75.0) | 5 (100.0) | 31 (93.9) | |
| Positive | 4 (6.3) | 11 (25.0) | 0 (0.0) | 2 (6.1) | |
| Vimentin | 0.000 | ||||
| Negative | 38 (60.3) | 32 (72.7) | 3 (60.0) | 8 (24.2) | |
| Positive | 25 (39.7) | 12 (27.3) | 2 (40.0) | 25 (75.8) | |
| Aldehyde dehydrogenase 1 | 0.378 | ||||
| Grade 0 | 23 (36.5) | 8 (18.2) | 2 (40.0) | 12 (36.4) | |
| Grade 1+ | 7 (11.1) | 6 (13.6) | 1 (20.0) | 6 (18.2) | |
| Grade 2+ | 14 (22.2) | 8 (18.2) | 1 (20.0) | 5 (15.2) | |
| Grade 3+ | 19 (30.2) | 22 (50.0) | 1 (20.0) | 10 (30.3) | |
CD, cluster of differentiation.